6 0 • O U T P A T I E N T S U R G E R Y M A G A Z I N E • J U L Y 2 0 2 0
EyePoint Pharmaceuticals | Dexycu
It's generally accepted that cataract patients don't like postoperative
steroid drops, which can lead to compliance problems. That's why
injectable anti-inflammatory drugs like this one that reduce or remove
the need for drops are of great interest. At virtual ASCRS, EyePoint
presented positive retrospective case study data supporting Dexycu.
They also seized on the COVID-19 issue by pointing out the drug can
reduce follow-up clinic visits and thus limit physician and caregiver
contact. Like many things during this volatile time in surgery, this
drug is moving from a nice-to-have to a must-have for many ophthal-
mologists.
